Industry committee  Thank you very much for the question. There are maybe just a couple of quick things. I will try to be very brief. In my reference to October 2020, the strategy was to identify, following expert scientific advice, which candidate vaccines had the greatest promise to come to marke

Industry committee  There are a couple of quick things. I think it's an unavoidable reality that the manufacturing of these vaccines and the fitting up of these facilities takes years. If you look at a typical or even an aggressive schedule for building and qualifying, these are extraordinarily tech

Industry committee  There's a period of reflection that's happening right now. We're still in the pandemic. We're all hopeful that it's in the rear-view mirror soon enough. I think across government, you're going to see many of us reflecting on the experience of what worked and what didn't, or what

Industry committee  Thank you for the question. I think maybe there are two dimensions to the answer. One of course would have to do with Canada's donation strategy.

Industry committee  I'll look to maybe Maria, who could probably offer a thought on the time-frame element of your question around getting vaccines when the facility is qualified and when they're rolling off the line. Novavax would probably be the first example of that. Perhaps Maria, you might be

Industry committee  Thank you for the question. I will say off the top that you're asking a question that is not really in my area of expertise, nor in my colleagues'. If we have time, I might turn to my colleague Darryl Patterson, who could offer a few views. You're asking a very big question abo

Industry committee  In terms of red tape reduction, it's an interesting question. I have a few thoughts in response. I think there are opportunities that probably exist on multiple levels. Some of these have proven themselves over the past 18 months, where you've seen a level of agility and speedin

Industry committee  In terms of examples, I may turn to Rodrigo. In the early stage of the pandemic, there were a number of significant funding decisions that were made, early on and in a very compressed time frame, that have proven to be highly advantageous. Rodrigo, could you provide a couple of

Industry committee  Thank you so much for the question. Your question raises a number of really important issues, the first of which is that Medicago is, first and foremost, a vaccine manufacturing firm that is not controlled by PMI. It is completely independent. It operates in and around Quebec Ci

Industry committee  If we look back to last year's budget and the commitment to $2.2 billion, which is in addition to the $1.6 billion that has been spent to date, that's the marker for funding the strategy. Of the $2.2 billion, approximately $1 billion is dedicated to various research undertakings,

Industry committee  Go ahead, Maria.

Industry committee  If it's okay, I might turn to my colleague Darryl Patterson to answer that part of the question.

Industry committee  As I said in my first answer, we did know. It's part of the due diligence process and looking at the financial situation of the company. Part of that is an examination of the ownership structure. There was an awareness at the outset that PMI had a minority position over Medicago.

Industry committee  I will turn to my colleague Daniel Quinn, who has oversight over research infrastructure and can probably provide you some information regarding the process for laboratory approvals. Daniel.

Industry committee  Again, thank you very much for the question. At the time of the investment, it really was an investment in their vaccine candidate and looking to get an effective and safe vaccine to market as soon as possible. The ownership structure and the challenge that it might present to